AChE

Positive results from a planned overall survival ( OS ) interim analysis of the phase 3 head-to-head ENDEAVOR trial were...


There is general consensus about the large and persuasive body of evidence that statins are effective and safe in reducing...


The FDA ( U.S. Food and Drug Administration ) has approved Siliq ( Brodalumab ) to treat adults with moderate-to-severe...



The FDA ( U.S. Food and Drug Administration ) has granted accelerated approval to Keytruda ( Pembrolizumab ) for the...


The U.S. Food and Drug Administration ( FDA ) has approved Ocrevus ( Ocrelizumab ) as the first and only...


Amyotrophic lateral sclerosis ( ALS ) is a rapidly progressing neurodegenerative disease that is characterized by motor neuron loss and...


Results from two phase 3 studies of the Tezacaftor ( VX-661 ) / Ivacaftor combination treatment that showed statistically significant...


The European Commission ( EC ) has granted Conditional Marketing Authorisation for Natpar ( rhPTH [ 1-84 ] ), the...


Multiple sclerosis ( MS ) is increasingly being viewed and studied not only as an immune-mediated demyelinating and neurodegenerative disease...


As the Zika virus continues to spread globally, new evidence has emerged about the virus's potentially detrimental effects on the...


The indoleamine 2,3-dioxygenase ( IDO ) pathway is a key counter-regulatory mechanism that normally inhibits immune responses when appropriate. In...


A new analysis from a pivotal study highlighting the efficacy of Erenumab in patients with 15 or more headache days...


Effective anti-tumour immunity in humans has been associated with the presence of T cells directed at cancer neoantigens, a class...


Data from the pivotal phase 3 LATITUDE clinical trial showed Abiraterone acetate ( Zytiga ) plus Prednisone, in combination with...


The European Commission ( EC ) has granted marketing authorization for Vosevi ( Sofosbuvir 400mg / Velpatasvir 100mg / Voxilaprevir...


Kymriah ( Tisagenlecleucel ), a cell-based gene therapy, is approved in the United States for the treatment of patients up...


The US Food and Drug Administration ( FDA ) has approved Kymriah ( Tisagenlecleucel ) suspension for intravenous infusion, formerly...


Updated results from the phase 3 KEYNOTE-045 trial evaluating Pembrolizumab ( Keytruda ), an anti-PD-1 therapy, in patients with locally...


Data from all three cohorts of the registrational, phase 2 KEYNOTE-059 trial investigating the use of Pembrolizumab ( Keytruda ),...